Malcolm Mason

1.0k total citations · 1 hit paper
14 papers, 683 citations indexed

About

Malcolm Mason is a scholar working on Pulmonary and Respiratory Medicine, Surgery and Oncology. According to data from OpenAlex, Malcolm Mason has authored 14 papers receiving a total of 683 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Pulmonary and Respiratory Medicine, 7 papers in Surgery and 3 papers in Oncology. Recurrent topics in Malcolm Mason's work include Prostate Cancer Diagnosis and Treatment (5 papers), Prostate Cancer Treatment and Research (5 papers) and Bladder and Urothelial Cancer Treatments (4 papers). Malcolm Mason is often cited by papers focused on Prostate Cancer Diagnosis and Treatment (5 papers), Prostate Cancer Treatment and Research (5 papers) and Bladder and Urothelial Cancer Treatments (4 papers). Malcolm Mason collaborates with scholars based in United Kingdom, United States and Italy. Malcolm Mason's co-authors include Mahesh Parmar, Peter Kirkbride, Jim Barber, Jinka Sathya, Charles Hayter, Mary Gospodarowicz, Karen Sanders, Matthew R. Sydes, Edmund Kostashuk and John Anderson and has published in prestigious journals such as The Lancet, Cancer Research and The Journal of Urology.

In The Last Decade

Malcolm Mason

13 papers receiving 669 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial

2011 382 citations Padraig Warde, Malcolm Mason et al. The Lancet profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Malcolm Mason United Kingdom	8	432	257	144	80	78	14	683
Masaomi Ikeda Japan	13	179 0.4×	197 0.8×	103 0.7×	101 1.3×	14 0.2×	65	468
M.V. Pilepich United States	13	456 1.1×	100 0.4×	170 1.2×	91 1.1×	140 1.8×	30	775
Antonio Puras-Báez Puerto Rico	6	530 1.2×	133 0.5×	42 0.3×	21 0.3×	34 0.4×	8	609
Matthew D. Katz United States	9	294 0.7×	248 1.0×	86 0.6×	125 1.6×	6 0.1×	19	506
Naotaka Sakamoto Japan	16	250 0.6×	244 0.9×	220 1.5×	125 1.6×	5 0.1×	50	560
Ross Snow Australia	9	279 0.6×	92 0.4×	46 0.3×	50 0.6×	26 0.3×	13	343
Justine Varinot France	14	175 0.4×	388 1.5×	112 0.8×	104 1.3×	4 0.1×	39	619
William J. Terry United States	8	714 1.7×	184 0.7×	114 0.8×	53 0.7×	5 0.1×	11	830
Hong Hong Huang Singapore	12	220 0.5×	111 0.4×	120 0.8×	52 0.7×	3 0.0×	38	379
Hillel Kahane United States	14	571 1.3×	197 0.8×	68 0.5×	71 0.9×	4 0.1×	23	713

Countries citing papers authored by Malcolm Mason

Since Specialization

Citations

This map shows the geographic impact of Malcolm Mason's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Malcolm Mason with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Malcolm Mason more than expected).

Fields of papers citing papers by Malcolm Mason

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Malcolm Mason. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Malcolm Mason. The network helps show where Malcolm Mason may publish in the future.

Co-authorship network of co-authors of Malcolm Mason

This figure shows the co-authorship network connecting the top 25 collaborators of Malcolm Mason. A scholar is included among the top collaborators of Malcolm Mason based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Malcolm Mason. Malcolm Mason is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

14 of 14 papers shown

Henry, Ann, S. Rodda, Malcolm Mason, et al.. (2015). The Effect of Dose and Quality Assurance in Early Prostate Cancer Treated with Low Dose Rate Brachytherapy as Monotherapy. Clinical Oncology. 27(7). 382–386. 5 indexed citations

Ghazaly, Essam, Magdalena Ślusarczyk, Malcolm Mason, et al.. (2014). NUC-1031: A novel ProTide that overcomes the key cancer resistance mechanisms associated with poor survival. Cancer Research. 74. 2 indexed citations

Musunuru, Hima Bindu, Malcolm Mason, Louise Murray, et al.. (2014). Second Primary Cancers Occurring after I-125 Brachytherapy as Monotherapy for Early Prostate Cancer. Clinical Oncology. 26(4). 210–215. 15 indexed citations

Ghazaly, Essam, Magdalena Ślusarczyk, Malcolm Mason, et al.. (2014). Abstract CT401: NUC-1031: A novel ProTide that overcomes the key cancer resistance mechanisms associated with poor survival. Cancer Research. 74(19_Supplement). CT401–CT401. 5 indexed citations

Jiang, Wen G., et al.. (2013). Inhibitory effect of Yangzheng Xiaoji on the ARK/Aurora pathways and in vivo tumour growth of human osteosarcoma. ORCA Online Research @Cardiff (Cardiff University).

Bahl, Amit, Zafar Malik, Alison Birtle, et al.. (2013). 715 CABAZITAXEL FOR METASTATIC CASTRATION RESISTANT PROSTATE CANCER (MCRPC): FINAL QUALITY OF LIFE (QOL) RESULTS WITH SAFETY DATA FROM THE UNITED KINGDOM (UK) EARLY ACCESS PROGRAMME (EAP) (NCT01254279). The Journal of Urology. 189(4S). 6 indexed citations

Meeks, Joshua J., Joaquim Bellmunt, Bernard H. Bochner, et al.. (2012). A Systematic Review of Neoadjuvant and Adjuvant Chemotherapy for Muscle-invasive Bladder Cancer. European Urology. 62(3). 523–533. 168 indexed citations

Wolff, J.M. & Malcolm Mason. (2012). Drivers for change in the management of prostate cancer – Guidelines and new treatment techniques. British Journal of Urology. 109(s6). 33–41. 18 indexed citations

Henry, Ann, Hima Bindu Musunuru, Malcolm Mason, et al.. (2012). Second Primary Cancers Occurring After I-125 Brachytherapy as Monotherapy for Early Prostate Cancer. International Journal of Radiation Oncology*Biology*Physics. 84(3). S16–S16. 2 indexed citations

10.

Warde, Padraig, Malcolm Mason, Keyue Ding, et al.. (2011). Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial. The Lancet. 378(9809). 2104–2111. 382 indexed citations breakdown →

11.

Cooper, Rachel, et al.. (2010). Defunctioning stomas prior to chemoradiation for anal cancer are usually permanent. Colorectal Disease. 14(1). 87–91. 15 indexed citations

12.

Mason, Malcolm. (2006). Re: Intravesical Bacillus Calmette-Guerin versus Mitomycin C for Ta and T1 Bladder Cancer Shelley MD, Court JB, Kynaston H, Wilt TJ, Coles B,. 16 indexed citations

13.

Abulrob, Abedelnasser, Malcolm Mason, Richard Bryce, & Mark Gumbleton. (2000). The Effect of Fatty Acids and Analogues upon Intracellular Levels of Doxorubicin in Cells Displaying P-Glycoprotein Mediated Multidrug Resistance. Journal of drug targeting. 8(4). 247–256. 25 indexed citations

14.

Hockey, Meghan, J W L Fielding, Karen Kelly, et al.. (1984). Resection line disease in stomach cancer. British Stomach Cancer Group.. BMJ. 289(6445). 601–603. 24 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact